Evidence map›Paper›PMID 37394561›Full record

SynthesisJournal of thrombosis and thrombolysis2023

Multiple sclerosis and the incidence of venous thromboembolism: a systematic review and meta-analysis.

Hamed Ghoshouni, Behnam Shafaei, Mahour Farzan, Seyedeh Melika Hashemi, Alireza Afshari-Safavi, Elham Moases Ghaffary, Mahtab Mohammadzamani, Vahid Shaygannejad, Alireza Sepehri Shamloo, Omid Mirmosayyeb

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of thrombosis and thrombolysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Hamed GhoshouniIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Behnam ShafaeiIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mahour FarzanIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Seyedeh Melika HashemiIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Alireza Afshari-SafaviDepartment of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Elham Moases GhaffaryIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mahtab MohammadzamaniIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Vahid ShaygannejadIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Alireza Sepehri ShamlooDepartment of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.
Omid MirmosayyebIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. omid.mirmosayyeb@gmail.com.
Isfahan University of Medical Sciences · IRNorth Khorasan University of Medical Sciences · IRLeipzig Heart Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A number of studies have suggested that multiple sclerosis (MS) can be associated with serious vascular complications, for which pulmonary thromboembolism (PTE) is a potentially lethal complication. The purpose of this study is to establish a current literature-based estimate of the incidence of venous thromboembolism (VTE), deep vein thrombosis (DVT), and PTE in patients with MS (pwMS) due to the lack of systematic reviews and meta-analyses on this topic. In this systematic review and meta-analysis, studies were assessed regarding the association between MS and the incidence of VTE. The studies were identified through a systematic search of major electronic databases spanning the period from 1950 to February 2022. A random-effects analysis was conducted to calculate the pooled effect size (ES) and 95% confidence intervals (CI) using STATA software. Nine out of 4605 studies were included in the meta-analysis, with an overall sample size of 158,546 individuals. Meta-analysis revealed that the pooled incidence of VTE was 1.8% (95% CI 1.4-2.3) among pwMS. Also, there was an incidence of 0.9% (95% CI 0.4-1.4) and 1.5% (95% CI 1-2.2) for PTE and DVT, respectively in pwMS. Analysis showed MS would be significantly associated with a twofold increased risk of VTE [risk ratios (RR) = 2.12 (95% CI 1.53-2.93)]. Although MS is not typically considered a major risk factor for VTE, the meta-analysis of cohort studies shows that MS has a relative association with an increased incidence of VTE. Future research should focus on the investigation of the effects of MS and its treatments on VTE risk, and also a full range of confounding adjustments will be needed.

Indexed as

Multiple SclerosisPulmonary EmbolismVenous ThromboembolismVenous ThrombosisHumansIncidenceRisk FactorsDeep vein thrombosisMultiple sclerosisVein thrombosisVenous thromboembolism

Identifiers

PMID37394561
OpenAlexW4382894276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.